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Abstract
Using the NADH-CoQ reductase of Rhodobacter capsulatus as a model for the mitochondrial Complex I, we have for
the first time isolated bacterial mutants resistant to piericidin-A, a classical inhibitor of the mitochondrial enzyme. Their
sensitivity to other inhibitors directed towards the quinone binding domain of complex I gives direct genetic evidence for
the existence of two inhibitor binding sites.q 1977 Elsevier Science B.V. All rights reserved.
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The mitochondrial NADH-CoQ reductase or Com-
plex I catalyses the first step of mitochondrial respira-
tion. Bovine Complex I is composed of 43 subunits
divided into two parts: an hydrophilic domain bearing
the catalytic NADH binding site and a hydrophobic
w xone where proton pumping must take place 1 . Based
on the observation of bound semiquinones associated
with Complex I it has been proposed that quinone
 .binding site s might take part in an elaborate proton
w xpumping mechanism reminiscent to the Q-cycle 2 .
Alternatively, according to the ‘dual gated model’,
two quinones bound to two different quinone sites are
gating proton transfer through a redox switch from
w xthe quinone to semiquinone state 3 . Despite the fact
that the existence of several quinone binding sites is
strongly suggested by characterization of Complex I
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w xinhibitors 3–8 , the relationship between quinone
and inhibitors binding sites still remains unclear. The
membranous domain of Complex I which must house
 .the quinone binding site s is essentially composed of
the seven mitochondrially encoded ND subunits. Ge-
netic approaches are therefore difficult even in lower
eucaryotes. Moreover, it is rather difficult to study
these highly hydrophobic proteins by classical bio-
chemical approaches. For these reasons we developed
a bacterial model of Complex I in Rhodobacter
capsulatus. Indeed, the bacterial type-I NADH-CoQ
 .reductases NDHs are multimeric enzymes which
present seven subunits equivalent to the mitochon-
w xdrial NDs 9–12 . The genes for these bacterial NDs
are clustered in the bacterial nuo operon. Unlike the
w xtype-I NDH of Escherichia coli 5 , the enzyme of
R. capsulatus is highly sensitive to the potent in-
hibitor of mitochondrial complex I, piericidin-A. We
therefore used this model to isolate bacterial pieri-
cidin resistant mutants.
Piericidin-A was isolated as described by Tamura
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w x13 and was purified by HPLC on an Hypersil
column. In preliminary experiments, we observed
that growth of W1 a home-made kanamycin resistant
.derivative of R. capsulatus B10 strain on RcV
w xmalate 14 , in the dark, at 308C, was severely re-
pressed by the presence of 5 mM piericidin-A but
was never completely prevented. We noted the pres-
ence of some colonies growing far more efficiently
than the others. Unfortunately, characterization of
these strains proved disappointing as they were not
piericidin resistant at the complex I level. Other
independant observations made in the laboratory:
complex I deficient mutants are able to grow aerobi-
cally on RcV malate, in the dark, using the end of the
w xrespiratory chain to energize theirs membranes 15 .
However, at the difference with wild type, these
mutants are unable to grow in the presence of myxo-
thiazol. As piericidin inhibition should reproduce a
situation similar to complex I deficiency, we infered
from our experiments with complex I deficient mu-
tants that addition of myxothiazol together with pieri-
cidin should strengthen the piericidin resistance
screening. In practice, we spread about 4P109 bacte-
ria per RcV malate plate on four plates containing 2.5
mM piericidin-A and 10 mM myxothiazol. This
screening allowed the isolation of about 20 colonies
per plate. As myxothiazol totally inhibits photosyn-
thetic growth of R. capsulatus by blockade of the
w xcyclic photosynthesis 16 , it was easy to eliminate
mutants resistant to this inhibitor in a second screen-
ing: 40 colonies isolated on the piericidin-myxothia-
zol medium were grown in parallel in photosynthetic
conditions plus myxothiazol or in dark-aerobic condi-
tions. This second screening showed that 36 of the
isolated colonies were actually myxothiazol resistant.
However, the four colonies unable to grow in
‘myxothiazol-photosynthesis’ conditions appeared to
be resistant to piericidin-A and sensitive to myxothia-
zol. These mutants were called PiA, PiB, PiC and
PiD, respectively. The following study deals with the
characterization of mutants PiC and PiD.
High concentrations of both piericidin and myxo-
thiazol are reported to cross-inhibit Complex III and
w xComplex I of mitochondria 17 . Furthermore, the
piericidin-A concentration required for complete inhi-
bition of R. capsulatus growth is about 104 times the
apparent K of the type-I NDH measured on isolatedi
 .membranes see below . To confirm that the pieri-
Fig. 1. Sensitivity of the NADH oxidase activity of wild-type and
P mutant membranes to piericidin A. Panel A: titration of thei
effect of piericidin on the NDH of P mutants. 0.1 mg mem-i
 .branes aliquots of wild-type control circles or mutants PiC
 .  .squares and PiD diamonds were incubated for 5 min at 308C,
in the presence of variable amounts of piericidin. The NADH
oxidase activity was then recorded spectrophotometrically at
 y1 y1.308C e s6200 M Pcm . To check for the possible contri-340
bution of type-II NDH in the observed resistance the experiment
 .was repeated with either NADH open symbols or deaminoN-
 .ADH closed symbols as a substrate. Panel B: effect of the
protein concentration on the apparent I for piericidin of PiC50
and PiD mutants. This panel presents a synthesis of a series of
experiments conducted mainly as in panel A but with variable
amounts of added membranes. The circles represent I values50
estimated on wild-type membranes, the squares are associated
with PiC and the diamonds with PiD. Extrapolation to zero
protein gives apparent K values of 0.2 nM, 5.5 nM and 6.5 nMi
for the NDHs of wild-type control, PiC and PiD, respectively.
cidin-A resistance seen on plates was truly associated
with Complex I, the effect of piericidin on the NADH
oxidase activity was titrated on isolated membranes
of Pi mutants and of wild type strain. As shown in
Fig. 1 the NADH oxidase activity associated with Pi
mutant membranes is definitely resistant to pieri-
cidin-A. This piericidin resistant oxidase activity
could have resulted in the mutants, from the expres-
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sion of a type-II NDH which is a small homodimeric
enzyme encountered in some bacterial species and
w xunrelated to the mitochondrial complex I 9 . How-
ever, all the present observations were unmodified
when NADH was replaced by deamino-NADH which
 .is specifically oxidized by the type-I NDH Fig. 1A .
The maximal inhibition of NADH oxidase activity
associated with mutant and wild type membranes
reached 95%. Thus for both mutants, the resistance
must result simply from a decrease of the affinity of
type-I NDH for piericidin-A. From titrations of the
I of piericidin as a function of membrane protein50
w xconcentration 4 , we calculated an apparent K ofi
0.2 nM, 5.5 nM and 6.5 nM for the NDHs of W1,
 .PiC and PiD, respectively Fig. 1B . The mutants K i
are thus about 30 times the apparent K displayed byi
the wild type NDH. These apparent K values werei
obtain for an incubation time with inhibitors deliber-
ately limited to 5 min as the NADH oxidase activity
strongly decreases when membranes are kept diluted
at 308C. Similar measurements made after 1 h re-
vealed that the activity was reduced by more than a
half with a concomitant decrease of inhibitors sensi-
tivity by a factor 1.5–2. Nevertheless, the ratio of
apparent affinity between wild type and resistant
mutants remained unchanged. We observed that the
piericidin resistance could be transferred by homolo-
gous recombination between the wild type genome
and a suicide plasmid bearing all the 3X part of the
nuo operon of mutants PiC and PiD. Different kinetic
Fig. 2. Effect of rotenone on the NADH oxidase activity of
mutant membranes. This figure illustrates the sensitivity of our
mutants to rotenone. NADH-oxidase activity was recorded on 0.1
 .mg of membranes of wild-type control circles , PiC mutant
 .  .squares or PiD mutant diamonds after preincubation for 5 min
at 308C with various concentrations of inhibitor.
Fig. 3. Effect of rolliniastatin-2 on the NADH oxidase activity of
mutant membranes. This figure illustrates the sensitivity of our
mutants to rolliniastatin-2. NADH-oxidase activity was recorded
 .on 0.1 mg of membranes of wild-type control circles , PiC
 .  .mutant squares or PiD mutant diamonds after preincubation
for 5 min at 308C with various concentrations of inhibitor.
data have suggested the presence of two classes of
inhibitors for mitochondrial Complex I, which can be
 .exemplified by rolliniastatin site A and rotenone
 . w xsite B 3–8 . Although classically described as site
A inhibitor for the mitochondrial complex I, pieri-
cidin is considered to bind also the rotenone binding
w xsite 3,4 . We thus further studied the effect of the
two ‘site specific’ inhibitors: rotenone and rollinias-
 .tatin-2, in order to confirm or unvalidate the exis-
tence of these two classes of inhibitors binding sites
and, to determine which of these sites was affected in
our resistant mutants. Titrations of the inhibition of
NADH oxidase activity on the membranes of PiC and
PiD mutants clearly demonstrated that the piericidin
resistant mutants are also resistant to rotenone Fig.
.2 but display an unmodified sensitivity to rollinias-
 .tatin-2 Fig. 3 . Thus, according to the present knowl-
 .edge on Complex I inhibitor binding sites see above ,
our mutants are clearly altered in the B site shared by
rotenone and piericidin-A but not altered in the A site
w xinhibited by rolliniastatin-2 3,4,18 . These observa-
tions constitute the first genetic evidence to validate
the existence of the A and B sites predicted by
enzymologic studies. In theory, minor genetic alter-
ation can lead to an extensive reorganization of the
overall structure of a protein. However, the fact that
our mutants keep a high enzymatic activity about
65% and 80% of wild type activity for PiC and PiD,
.respectively and display a very selective change in
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their sensitivity to Complex I inhibitors indicates that
the structural alterations must be limited.
To try and get a better picture of the inhibitor
binding sites, our promising genetic approach is de-
veloped in three directions: first we are physically
mapping the genetic alterations associated with the
resistance observed in the isolated Pi mutants. This
mapping is an original and elegant way to allow the
physical characterization of the inhibitors binding
sites. Secondly, in collaboration with other groups,
we are pursuing the kinetic characterization of the
sensitivity of our mutants to other known inhibitors
of Complex I to help clarify the classification of the
inhibitors binding sites. Thirdly, other inhibitor resis-
tant mutants have to be isolated to get a full panorama
of the inhibitor binding sites.
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